
icon
-
Novartis ranks first in 2024 Access to Medicine Index
-
Negative impact of the IRA on patient access to innovative treatments
-
Sickle cell screening urged for newborns in Africa
-
Boosting access to cancer care where it’s needed most
-
Prioritizing the needs of patients
-
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
-
Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions
-
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
-
Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics
-
Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
-
Novartis Access impact evaluation: progress update on our work with Boston University
-
Novartis invites scrutiny of effort to improve access to medicine